Transmedics opened lower at $91.65, compared with its previous close of $92.01. In the last trading session, the stock traded between $90.77 and $96.46. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Transmedics is now worth
$ 340.80
Giving a profit of
$ 240.80 (240.80%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-0.10 (-0.10%)
Day High
$96.46
Day Low
$90.77
Day Open
$91.65
Prev Close
$92.01
Volume
8,99,429
1W Return
26.32%
1M Return
17.62%
3M Return
2.86%
6M Return
42.95%
1Y Return
-24.75%
Market Cap ($ Mn)
3,193
PE Ratio
22.91
PB Ratio
5.91
PEG Ratio
0.23
ROE
57.97%
ROCE
14.42%
EPS (TTM)
$0.49
1 Week
26.32%
1 Month
17.62%
3 Months
2.86%
6 Months
42.95%
9 Months
-31.05%
Halper Sadeh investigates TransMedics for potential fiduciary breaches
Halper Sadeh LLC is investigating TransMedics Group, Inc. for potential fiduciary duty breaches. Investigation focuses on actions by certain officers and directors. Long-term shareholders may seek governance reforms or financial recovery. Firm operates on a contingent fee basis with no upfront costs.
TodayUBS raises TransMedics price target to $88, maintains neutral rating
UBS raised its price target for TransMedics Group to $88 from $77. Analyst Patrick Wood maintained a Neutral rating on the stock. The new target is an increase of $11 over the previous benchmark. UBS's target remains below Needham's $110 and Canaccord Genuity's $120.
3 days agoHalper Sadeh investigates TransMedics for fiduciary duty breaches
Halper Sadeh LLC is investigating TransMedics Group for potential breaches of fiduciary duties by its officers and directors. Long-term shareholders may seek corporate governance reforms, return of funds, or court-approved incentive awards. The investigation was announced on September 26, 2026, with legal representation offered on a contingent fee basis.
1mo agoKahn Swick & Foti probes TransMedics over fraud allegations
Kahn Swick & Foti investigates TransMedics officers for fiduciary breaches. Probe follows Scorpion Capital report alleging fraud and unsafe practices. Securities class action lawsuit against company is already ongoing. Law firm seeks info from shareholders on potential legal rights.
1mo agoTransMedics appoints Araujo CFO, reiterates $737M-$757M FY26 guidance
TransMedics appoints Fernando Araujo as CFO effective September 21, 2026. Full-year 2026 revenue guidance remains $737 million to $757 million. Guidance implies 22% to 25% year-over-year growth. Revenue from PAD Aviation Service GmbH is excluded from the outlook.
2mo agoHalper Sadeh joins probe into TransMedics insider fiduciary duties
Halper Sadeh LLC launched a Sept 7, 2026 probe into TransMedics insider fiduciary duties. Rosen Law continues its own separate investigation announced on Aug 31, 2026. Shareholders may seek governance reforms or financial incentives through Halper Sadeh. Both firms operate on a contingent fee basis with no upfront costs to investors.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Transmedics is now worth
$ 340.80
Giving a profit of
$ 240.80 (240.80%)
Note: Past profits do not guarantee future returns.
